ClinicalTrials.gg
RecruitingNCT07440186STROMCOL3DUpdated Oct 20, 2026

Exploratory Clinical Research for the Evaluation of Human GMP (Good Manufacturing Practice) Collagen Implants (Humabiologics) in the Treatment of Corneal Melting (RCJ-COL3D-MC-01-2026)

An interventional study of 3D collagen implant printed under GMP conditions. in Patients With Severe Corneal Melting, sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 20, 2026Now RecruitingFirst site in Spain+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Participants will be invited to participate in this clinical study because they have a severe corneal melting. An eye disease characterized by the progressive loss of the transparent tissue that covers the eye (the cornea). This condition can cause pain, vision loss, and risk of eye perforation. Furthermore, in some cases, the response to standard treatments is inadequate.

A piece of 3D-printed human collagen will be implanted on the affected surface of the eye in order to reinforce and protect it and prevent its progression to perforation.

The collagen piece is biocompatible, flexible, and transparent, designed to integrate naturally with the eye's tissues. Since it does not require a complete transplant or a human donor at the time of surgery, it reduces the risks of rejection and complications associated with other more invasive techniques.

Read the detailed description

The 3D-printed collagen will be used in clinical research as a biocompatible graft for the treatment of severe corneal melting, providing structural support and promoting epithelial regeneration without the need for more invasive transplants.

02

Conditions studied

  • Patients With Severe Corneal Melting

Keywords

  • Corneal melting
03

In context

Lead sponsor

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal is the lead sponsor of 84 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age over 18 years.
  2. Patients who, after receiving detailed information about the design, purpose, risks, and implications of the study, and about their right to withdraw at any time without repercussions, give their informed written consent.
  3. Confirmed diagnosis of severe corneal melting.
  4. Absence of response to conventional non-surgical treatments, which must include:

    • Intensive antibiotic, antifungal, or antiviral treatment according to etiology.
    • Anti-inflammatory or immunomodulatory eye drops (such as , cyclosporine, tacrolimus).
    • Intensive lubrication and/or autologous serum.
    • Use of therapeutic contact lenses.
    • The patient must not have responded satisfactorily to these measures and must show progression or persistence of the ulcer, thinning, and structural risk.

    The absence of response is not defined by a specific number of treatments, but by the lack of clinical improvement or progression of the condition despite having received several of these measures appropriately. In particular, progression of the epithelial defect, worsening stromal thinning, or the appearance of signs of perforation risk will be considered an absence of response, which would justify surgical intervention.

  5. If the patient has previously undergone surgical procedures or received other implants (such as amniotic membrane, conjunctival flap, or Tenon's graft), this will be included if there is documented clinical progression without sufficient functional or structural recovery, and provided that there are no surgical alternatives with documented superior efficacy in their specific situation.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or breastfeeding.
  2. Refusal to participate in the study.
  3. Presence of active eye infection.
  4. Systemic diseases that may affect healing.
  5. Known to collagen compounds.
  6. Any circumstance that, in the investigator's opinion, makes the patient's participation in the clinical research inadvisable.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    Only Group A. 3D collagen implant printed under GMP conditions.

    Group A. 3D collagen implant printed under GMP conditions.

    Device: 3D collagen implant printed under GMP conditions.

Interventions

  • Device3D collagen implant printed under GMP conditions.

    Given its exploratory nature, the study does not propose an equivalence threshold compared to standard treatments, but rather seeks to confirm the safety and clinical viability of the implant. It is expected that 3D-printed collagen will provide superior stromal support, with greater transparency and stability than other reconstructive techniques, such as amniotic membrane, conjunctival flaps, or tectonic grafts.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse reactions to evaluate the safety and biocompatibility of 3D-printed collagen in the corneal stroma of patients with severe corneal melting.

    Incidence and severity of adverse reactions (safety and biocompatibility)

    Time frame: During 12 months after the surgery

  2. Biocompatibility assessment: potential complications associated with the implant evaluated by slit lamp biomicroscopy

    Biocompatibility assessment by slit lamp biomicroscopy * Epithelial status: Not assessable , Reason: Lens /Tarsorrhaphy/ Edema or Other // Assessable : Epithelial defect present: Yes /No, Size of defect (if assessable) mm², Edges: Regular/ Irregular * Overall corneal edema: Mild /Moderate / Severe * Infiltrate: No /Yes (describe) * Vascularization (scale 0-3) * Secretion: Absent /Mild /Moderate / Profuse * Signs of infection: No / Yes (describe)

    Time frame: During 12 months after the surgery

  3. Potential complications associated with the implant evaluated by Optical Coherence Tomography (OCT)

    Biocompatibility assessment by OCT: * If the graft is present: Integration (Adequate/Partial/Displacement/ Graft edema/ Partial resorption) // Minimum thickness ( µm) * If the graft is no longer present: ( Graft not visible/resorbed)

    Time frame: During 12 months after the surgery

Secondary outcomes

  1. Determine the rate and time of corneal epithelial re-epithelization after implantation

    Corneal re-epithelization rate and time measured with fluorescein staining. This will be measured as the area of the epithelial defect expressed in mm², which will allow both the rate of re-epithelialization and the time to complete closure to be calculated.

    Time frame: During 12 months after the surgery

  2. Determine the rate and time of corneal epithelial re-epithelialization after implantation

    Corneal thickness achieved in the area of corneal thinning by melting using Optical Coherence Tomography (OCT). This will be measured in μm.

    Time frame: During 12 months after the surgery

  3. Compare the inflammatory response with conventional treatments (amniotic membrane, conjunctival flap, adhesives)

    Slit lamp biomicroscopy, evaluating:Presence and degree of conjunctival hyperemia (scale of 0 to 3) and Stromal edema (scale 0-3)

    Time frame: During 12 months after the surgery.

  4. Compare the inflammatory response with conventional treatments (amniotic membrane, conjunctival flap, adhesives)

    Slit lamp biomicroscopy, evaluating: Loss of transparency (standardized subjective scale 0-3)

    Time frame: During 12 months after the surgery

  5. Compare the inflammatory response with conventional treatments (amniotic membrane, conjunctival flap, adhesives)

    Slit lamp biomicroscopy, evaluating: Presence of keratic precipitates, cells, and flare in the anterior chamber, if applicable.

    Time frame: During 12 months after the surgery

  6. Compare the inflammatory response with conventional treatments (amniotic membrane, conjunctival flap, adhesives) by photograph

    2\. Photograph of the anterior segment at each visit to document changes and allow for masked evaluation by external experts .

    Time frame: During 12 months after the surgery

  7. Quality of life scales: Visual quality and symptom questionnaires: Ocular Surface Disease Index (OSDI)

    The questions are responsed as Scale: 0 = None of the time, 1 = Some of the time, 2 = Half of the time, 3 = Most of the time, 4 = All of the time. According to the sum total of the questions: Severity Levels: Normal (0-12), Mild (13-22), Moderate (23-32), Severe (33-100)

    Time frame: 12 months since surgery

  8. Quality of life scales: Visual quality and symptom questionnaires: National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)

    High Scores (close to 100): Indicate little to no impairment in that specific area of life. Low Scores (closer to 0): Indicate significant difficulty or dependency caused by poor vision.

    Time frame: 12 months since surgery

  9. Quality of life scales: Visual quality and symptom questionnaires: Eye pain and discomfort scales

    Visual Analogue Scale (VAS) from 0 to 10 : Mild ( from 0 to 2), Moderate (from 3 to 7) and severe (from 8 to 10)

    Time frame: 12 months since surgery

  10. Quality of life scales: Visual quality and symptom questionnaires: Eye pain and discomfort scales: Symptom Likert scale

    (0 = none, 4 = very severe) to assess burning, photophobia, foreign body sensation, and tearing.

    Time frame: 12 months since surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Stokking M, Cadenas-Martín M, Martín-González AI, Fernández-Ferrer A, Arnalich-Montiel F, De Miguel MP. (2025). Three-dimensional-printed collagen scaffold with limbal stem cells derived from adipose-derived mesenchymal stem cells for the treatment of limbal stem cell deficiency. Int J Bioprinting, 11(6), 407-429. doi:10.36922/IJB025290293
  • Deshmukh R, Stevenson LJ, Vajpayee R. Management of corneal perforations: An update. Indian J Ophthalmol. 2020 Jan;68(1):7-14. doi: 10.4103/ijo.IJO_1151_19. PubMed 31856457 ↗
  • 10. Koenig KR, et al. "Biomaterials for corneal regeneration: Current perspectives." J Biomed Mater Res. 2020.
  • Vajpayee RB, Singhvi A, Sharma N, Sinha R. Penetrating keratoplasty for perforated corneal ulcers: preservation of iris by corneal debulking. Cornea. 2006 Jan;25(1):44-6. doi: 10.1097/01.ico.0000177834.85507.28. PubMed 16331040 ↗
  • Korah S, Selvin SS, Pradhan ZS, Jacob P, Kuriakose T. Tenons Patch Graft in the Management of Large Corneal Perforations. Cornea. 2016 May;35(5):696-9. doi: 10.1097/ICO.0000000000000808. PubMed 26989954 ↗
  • Hick S, Demers PE, Brunette I, La C, Mabon M, Duchesne B. Amniotic membrane transplantation and fibrin glue in the management of corneal ulcers and perforations: a review of 33 cases. Cornea. 2005 May;24(4):369-77. doi: 10.1097/01.ico.0000151547.08113.d1. PubMed 15829790 ↗
  • Solomon A, Meller D, Prabhasawat P, John T, Espana EM, Steuhl KP, Tseng SC. Amniotic membrane grafts for nontraumatic corneal perforations, descemetoceles, and deep ulcers. Ophthalmology. 2002 Apr;109(4):694-703. doi: 10.1016/s0161-6420(01)01032-6. PubMed 11927426 ↗
  • Lee SH, Tseng SC. Amniotic membrane transplantation for persistent epithelial defects with ulceration. Am J Ophthalmol. 1997 Mar;123(3):303-12. doi: 10.1016/s0002-9394(14)70125-4. PubMed 9063239 ↗
  • Sii F, Lee GA. Fibrin glue in the management of corneal melt. Clin Exp Ophthalmol. 2005 Oct;33(5):532-4. doi: 10.1111/j.1442-9071.2005.01076.x. PubMed 16181285 ↗
  • Lagoutte FM, Gauthier L, Comte PR. A fibrin sealant for perforated and preperforated corneal ulcers. Br J Ophthalmol. 1989 Sep;73(9):757-61. doi: 10.1136/bjo.73.9.757. PubMed 2804032 ↗
  • Setlik DE, Seldomridge DL, Adelman RA, Semchyshyn TM, Afshari NA. The effectiveness of isobutyl cyanoacrylate tissue adhesive for the treatment of corneal perforations. Am J Ophthalmol. 2005 Nov;140(5):920-1. doi: 10.1016/j.ajo.2005.04.062. PubMed 16310475 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Oct 2026, 7 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 27, 2026
StartActual
Mar 24, 2026was Feb 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
1 site added — first site in Spain
Show site
  • Hospital Universitario Ramón y Cajal · Madrid, Spain
Oct 20, 2026
Start date
Feb 28, 2026→Mar 24, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Spain
    Show site
    • Hospital Universitario Ramón y Cajal · Madrid, Spain
    Start date Feb 28, 2026→Mar 24, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07440186
Lead sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Collaborators
Instituto de Investigación Hospital Universitario La Paz, Instituto de Investigación Sanitaria Gregorio Marañón
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 24, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Francisco Arnalich-Montiel, MD
Contact
farnalich@gmail.com
+34913368126
María P. De Miguel, MD
Contact
mariapdemiguel@gmail.com
Francisco Arnalich-Montiel, MD
study director · Hospital Ramón y Cajal. Servicio de Oftalmología. Ctra. de Colmenar Km 9,100. 28034 Madrid
María P. De Miguel, MD
principal investigator · Instituto de Investigaciones Sanitarias del Hospital Universitario La Paz, IdiPAZ, Madrid

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion